Compare Eli Lilly And Co (LLY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vistra Corp — how do they compare? Eli Lilly And Co trades at $1,221.91 (market cap $1.08T), while Vistra Corp trades at $146.53 (market cap $48.64B). The key difference: Eli Lilly And Co is far larger — about 22.2× Vistra Corp's market cap, and Vistra Corp pays the higher dividend (0.63%). Which is the better fit depends on your goals.
| LLY | VST | |
|---|---|---|
Market Cap | $1.08T | $48.64B |
Sector | Health | Technology |
52-Week High | $1.24K | $217.92 |
52-Week Low | $639.43 | $134.71 |
Enterprise Value | $1.13T | $70.58B |
Dividend Yield | 0.57% | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
VST trades at $146.36, up 2.44% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $1.767 billion adjusted EBITDA, beating expectations, while maintaining 2026 guidance. Valuation metrics show a P/E of 24.44 and robust profitability with 75.73% ROE, though recent earnings have been inconsistent with two misses in the last four quarters.
VST presents a compelling growth story driven by data center power demand and nuclear assets, with 90.9% analyst buy ratings and a $239.75 price target suggesting 64% upside. Key risks include ERCOT pricing volatility and hedging losses, while institutional interest remains strong with recent strategic acquisitions positioning the company for AI infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
